よむ、つかう、まなぶ。
04 参考資料１－１23価肺炎球菌莢膜ポリサッカライドワクチン（肺炎球菌ワクチン）ファクトシート (31 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_36630.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第22回 12／1）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
48．Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, et al. Influence
of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent
pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent
pneumococcal vaccination in adults 50 years and older. Vaccine. 31:3594-3602,2013.
49．Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The
immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide
vaccine in adults aged 50-80 years. Clin Infect Dis. 49:1318-1325, 2009.
50．de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison
of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly
adults:
conjugate vaccine
elicits
improved antibacterial immune responses and
immunological memory. Clin Infect Dis. 46:1015-1023,2008.
51．Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al.
Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines
in Alaska native adults 55-70 years of age. Clin Infect Dis 49:241-248,2009.
52．福住宗久、新橋玲子、島田智恵、鈴木 基、大石和徳. 成人侵襲性肺炎球菌感染症由来株の細菌
学的解析に関する研究．成人の侵襲性細菌サーベイランス構築に関する研究（厚生労働科学研究
費補助金 新興・再興感染症及び予防接種政策推進研究事業 研究代表者：大石和徳）平成 29 年
度総括・分担研究報告書 p63-66. 2018 年 3 月
53．Singleton RJ, Butler JC, Bulkow LR, Hurburt D, O’Brien KL, Doan W, et al. Invasive
pneumococcal
disease
epidemiology
and
effectiveness
of
23-valent
pneumococcal
polysaccharide vaccine in Alaska native adults. Vaccine. 2007;25
54．Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent
pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly
in England and Wales. Vaccine. 2012;30
55．Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador
E, Lasheras Carbajo MD,et al. Effectiveness of 23-valent pneumococcal polysaccharide
vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. Euro
Surveill. 2014;19
56．Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al. Effectiveness of
pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly
30
of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent
pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent
pneumococcal vaccination in adults 50 years and older. Vaccine. 31:3594-3602,2013.
49．Goldblatt D, Southern J, Andrews N, Ashton L, Burbidge P, Woodgate S, et al. The
immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide
vaccine in adults aged 50-80 years. Clin Infect Dis. 49:1318-1325, 2009.
50．de Roux A, Schmole-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, et al. Comparison
of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly
adults:
conjugate vaccine
elicits
improved antibacterial immune responses and
immunological memory. Clin Infect Dis. 46:1015-1023,2008.
51．Miernyk KM, Butler JC, Bulkow LR, Singleton RJ, Hennessy TW, Dentinger CM, et al.
Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines
in Alaska native adults 55-70 years of age. Clin Infect Dis 49:241-248,2009.
52．福住宗久、新橋玲子、島田智恵、鈴木 基、大石和徳. 成人侵襲性肺炎球菌感染症由来株の細菌
学的解析に関する研究．成人の侵襲性細菌サーベイランス構築に関する研究（厚生労働科学研究
費補助金 新興・再興感染症及び予防接種政策推進研究事業 研究代表者：大石和徳）平成 29 年
度総括・分担研究報告書 p63-66. 2018 年 3 月
53．Singleton RJ, Butler JC, Bulkow LR, Hurburt D, O’Brien KL, Doan W, et al. Invasive
pneumococcal
disease
epidemiology
and
effectiveness
of
23-valent
pneumococcal
polysaccharide vaccine in Alaska native adults. Vaccine. 2007;25
54．Andrews NJ, Waight PA, George RC, Slack MPE, Miller E. Impact and effectiveness of 23-valent
pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly
in England and Wales. Vaccine. 2012;30
55．Gutierrez Rodriguez MA, Ordobas Gavin MA, Garcia-Comas L, Sanz Moreno JC, Cordoba Deorador
E, Lasheras Carbajo MD,et al. Effectiveness of 23-valent pneumococcal polysaccharide
vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008–2011. Euro
Surveill. 2014;19
56．Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, et al. Effectiveness of
pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly
30